Understanding Metabolic and Epigenetic Cross‐ talk in Potent Anti‐ tumor T cells

了解强效抗肿瘤 T 细胞中的代谢和表观遗传交叉对话

基本信息

批准号：
10400117
负责人：
Shikhar Mehrotra
金额：
$ 45.45万
依托单位：
MEDICAL UNIVERSITY OF SOUTH CAROLINA
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-05-12 至 2025-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10400117
关键词：
Acetylation Adoptive Cell Transfers Adoptive Transfer Aging Antibodies Antigens Antitumor Response Autologous Biological Process CD4 Positive T Lymphocytes CD8-Positive T-Lymphocytes CD8B1 gene Calcium Cell Death Cells Chromatin Clinical Data Deacetylation Dependence Energy Metabolism Epigenetic Process Epitopes Equilibrium Event Exhibits FOXP3 gene Failure Functional disorder Glutamine Helper-Inducer T-Lymphocyte Histone Deacetylase Homeostasis Human Human Engineering Hybrids Hydrolase IL2 gene Immune system Immunotherapy Interferon Type II Interleukin-17 Investigation Lead Malignant Neoplasms Mediating Memory Metabolic Metabolism Methylation Modality Modification Molecular Mus Natural Killer Cells Nicotinamide adenine dinucleotide PD-1 blockade PPBP gene Patients Phenotype Post-Translational Protein Processing Primary Neoplasm Property Proteins Protocols documentation Publishing Regulation Regulatory T-Lymphocyte Reporter Reporting Role SIRT1 gene Sirtuins Solid Neoplasm T cell response T cell therapy T memory cell T-Lymphocyte T-Lymphocyte Subsets TC1 Cell TNF gene Testing Th1 Cells Transferase Translating Tumor-Infiltrating Lymphocytes Work Xenograft Model anti-PD1 antibodies base cancer therapy clinical practice cofactor combinatorial cytokine engineered T cells epigenome exhaustion genetic signature improved improved outcome in vivo infectious disease model metabolic profile mitochondrial metabolism mouse model neoplasm immunotherapy novel pre-clinical preclinical study preservation programmed cell death protein 1 programs receptor response stem cell fate stem-like cell stemness transcriptome sequencing tumor tumor growth tumor microenvironment

项目摘要

ABSTRACT Recent preclinical studies have shown that different subsets of both helper CD4+ T helper (Th) cells and CD8+ T cytotoxic (Tc) cells hold promise for clinical use in adoptive cell therapy (ACT) protocols. Importantly, T helper cell subsets with the ability to secrete IL-17 (Th17) have been shown to possess stem cell like phenotype that attributes to their long-term persistence and leads to improved tumor control tumors as compared to the Th1 subsets (that secrete IFNγ, IL2, TNFα). However, contrary to these observations there are reports that Tc1 cells exhibit improved tumor control as compared to Tc17 cells. These differences in T cell subsets response to control tumors is compounded by the fact that in the suppressive tumor microenvironment a large fraction of tumor reactive T cells acquire FoxP3+ regulatory phenotype, become dysfunctional or undergo cell death leading to tumor reversion. Thus, ex vivo programming conditions that can render T cells a stable phenotype, which not only controls primary tumors but also results in the formation of anti-tumor memory will be of immense importance for ACT. We have recently established that programming conditions that bring together ‘anti-tumor effector function’ of Th1 cells and ‘stemness’ of Th17 cells lead to a superior hybrid Th1/17 cells exhibiting long-term tumor control. Importantly, these ex vivo programming conditions also generate highly effective hybrid Tc1/Tc17 cells and render human tumor infiltrating lymphocytes (TILs) with increased cytokine secreting ability. Importantly, the hybrid T cells exhibited higher levels of nicotinamide adenine dinucleotide (NAD+), a cofactor that serves as substrate for Sirtuins and regulates multiple metabolic and epigenetic molecules. We hypothesize that the robust long-term tumor control was observed with hybrid Th1/17 cells was mediated by an overall rejuvenated T cell phenotype due to high NAD+ that influenced a combination of events including post-translational modifications, and epigenetic stability that led to metabolically fit phenotype. Given the crucial role of NAD+ in a variety of biological processes including energy metabolism, aging, calcium homeostasis, and epigenome, we propose the following aims to test the above hypothesis: Aim 1) To determine if metabolic signature and anti-tumor phenotype of the cytokine subsets in hybrid T1/17 cells could be translated to program tumor infiltrating lymphocytes; Aim 2) To determine if antibody mediated combinatorial inhibition of CD38 with PD1 antibody leads to robust anti-tumor response in different preclinical in vivo and xenograft models; and Aim 3) To determine how NAD+ level contributes to metabolo-epigenetic programming that preserves robust anti-tumor response in T1/17 hybrid and CD38-KO T cells. We believe that this proposal to determine the central mechanism that results in superior anti-tumor response by hybrid T1/17 cells will be important to adapt these ex vivo programming conditions for immediate translational use in adoptive T-cell immunotherapy.

抽象的最近的临床前研究表明，辅助 CD4+ T 辅助 (Th) 细胞和 CD8+ 细胞的不同亚群 T 细胞毒性 (Tc) 细胞有望在过继细胞疗法 (ACT) 方案中得到临床应用。具有分泌 IL-17 (Th17) 能力的辅助细胞亚群已被证明具有干细胞样表型归因于它们的长期持续性并导致改善的肿瘤控制与 Th1 亚群（分泌 IFNγ、IL2、TNFα）相比，然而，与这些观察结果相反。据报道，与 Tc17 细胞相比，Tc1 细胞表现出更好的肿瘤控制能力。在抑制性肿瘤微环境中，亚群对对照肿瘤的反应更加复杂大部分肿瘤反应性 T 细胞获得 FoxP3+ 调节表型，变得功能失调或经历细胞死亡导致肿瘤逆转，因此，离体编程条件可以使 T 细胞成为一种细胞。稳定的表型，不仅能控制原发肿瘤，还能导致抗肿瘤细胞的形成记忆对于 ACT 来说非常重要，我们最近确定了这一编程条件。将 Th1 细胞的“抗肿瘤效应功能”和 Th17 细胞的“干性”结合在一起，产生了优越的效果混合 Th1/17 细胞表现出长期的肿瘤控制作用，这些离体编程条件也表现出长期的肿瘤控制作用。产生高效的杂交 Tc1/Tc17 细胞，并用人肿瘤浸润淋巴细胞 (TIL) 进行渲染重要的是，混合 T 细胞表现出更高水平的烟酰胺。腺嘌呤二核苷酸 (NAD+)，一种辅助因子，作为 Sirtuins 的底物并调节多种代谢我们追求通过杂交观察到强有力的长期肿瘤控制。 Th1/17 细胞是由整体恢复活力的 T 细胞表型介导的，这是由于高 NAD+ 影响了包括翻译后修饰和表观遗传稳定性在内的事件组合鉴于 NAD+ 在包括能量在内的多种生物过程中发挥着至关重要的作用。新陈代谢、衰老、钙稳态和表观基因组，我们提出以下目标来测试上述内容假设：目标 1) 确定细胞因子亚群的代谢特征和抗肿瘤表型是否杂交 T1/17 细胞可以转化为肿瘤浸润淋巴细胞；目的 2) 确定是否抗体介导的 CD38 与 PD1 抗体的组合抑制可在不同的临床前体内和异种移植模型；以及目标 3) 确定 NAD+ 水平如何发挥作用代谢表观遗传编程可在 T1/17 杂交和 CD38-KO T 中保持强大的抗肿瘤反应我们相信这一提议确定了产生卓越抗肿瘤作用的核心机制。杂交 T1/17 细胞的反应对于立即适应这些离体编程条件非常重要。过继性 T 细胞免疫疗法中的转化应用。